HOME >> BIOLOGY >> NEWS
UC Santa Barbara donates discovery to OneWorld Health that may speed disease treatment

(Santa Barbara, Calif.) The University of California, Santa Barbara announced today that it has donated all rights to a patent that covers the novel use of an established class of cardiovascular medicines as a potential new drug against a global parasitic disease. The Institute for OneWorld Health, a nonprofit pharmaceutical company based in San Francisco, will use the UCSB discovery and the wealth of data associated with the medicines to accelerate drug development for treatment of schistosomiasis.

Two UCSB researchers discovered that calcium channel blockers may prove to be an inexpensive alternative for controlling schistosome infection, a serious global health problem that afflicts more than 200 million people annually in developing nations. An estimated 200,000 people, many of them older children, die every year from schistosomiasis. Many more suffer chronic damage to vital organs, including the liver and bladder.

The inventors are Mark Walter, a research biologist, and Armand Kuris, professor of biology.

"Calcium channel blockers look very promising for the treatment of schistosomiasis, which is a devastating disease," said Kuris, an expert in parasitology and associate provost of the College of Creative Studies. Physicians routinely prescribe calcium channel blockers to treat high blood pressure, correct abnormal heart rhythms, treat panic attacks and bipolar disorder, and prevent migraine headaches.

"We know that the drugs are safe for people," said Kuris. "They are available, and not terribly expensive. For a tropical disease that is very, very important. We are gratified by OneWorld Health's interest in our discovery, and confident in its ability to develop this inexpensive treatment for schistosomiasis for children in rural villages throughout the world."

OneWorld Health partners with pharmaceutical and biotechnology companies, universities, government agencies, and global health advocates to develop comp
'"/>


24-Feb-2004


Page: 1 2 3

Related biology news :

1. UC Santa Barbara discovers cell survival gene may lead to treatments for degenerative diseases
2. Chemical society convenes regional meeting in Santa Barbara, October 28-31
3. Webcast will ensure broad public access to the UC Santa Cruz Public Forum on Human Genome Research
4. UC Santa Cruz Public Forum on the Human Genome
5. Coastal research project at UC Santa Cruz receives major boost in funding
6. UC Davis, Santa Barbara get $6 million to help estuaries
7. Future uses of MicroElectricalMechanical (MEM) systems to be featured at Santa Clara show
8. USGS Scientists To Speak On Rare Plants And Invasive Species At Santa Barbara Symposium
9. Kimberly-Clark Worldwide donates intellectual property to Rensselaer
10. Dupont donates patents to UCSD
11. Procter & Gamble donates proprietary "super aspirin" technology to Vanderbilt University

Post Your Comments:
(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...
(Date:6/18/2013)... June 18, 2013: The Association for Molecular Pathology is ... American Societies for Experimental Biology (FASEB) on July 1, ... on June 3, 2013. , The 26 constituent ... share a common vision for the advancement of research ... and translational research is more important now than ever," ...
(Date:6/18/2013)... that between 5% and 10% of breast and ovarian ... that these tumours are attributable to inherited mutations from ... In patients with these mutations, PARP inhibitors, which are ... make them a new option for personalised cancer treatment, ... indicate that a fraction of these patients generate resistance ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
(Date:6/19/2013)... Bayer CropScience will honor Illinois beekeeper Steve ... Leadership Award. The award will be announced at Bayer’s ... D.C., an event where supporters of pollinator health celebrate ... , The Bayer Bee Care Community Leadership Award ... honey bee colony to benefit their community. Applicants are ...
(Date:6/19/2013)... -- Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader SAP ... next week entitled "No Account Left Behind!  ... Help Keep Its Account Reconciliations in Good Shape ."  ... The webinar, geared at finance, accounting, audit and compliance managers ...
(Date:6/19/2013)... Indiana (PRWEB) June 19, 2013 ... joined the speaking faculty at 2013’s BioLogistics Summit ... The conference, coordinated by Cold Chain IQ and ... biologics. This “complexity” is, in part, attributed to ... , “Implicit within these trends is an ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
Breaking Biology Technology:Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2
Cached News: